Proffitt & Goodson’s Genmab GMAB Stock Holding History

Proffitt & Goodson’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-62	Closed	-$1.9K	–	363
2025 Q3	$1.9K	Buy	+62	New	+$1.51K	﹤0.01%	359

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Proffitt & Goodson's GMAB Position: Q4 2025 in Review

Proffitt & Goodson sold out of Genmab (GMAB) in Q4 2025, closing a stake of 62 shares — an estimated $1.9K sold.

Proffitt & Goodson first reported a position in GMAB in Q3 2025 and held it in 1 quarter. The position peaked at $1.9K in Q3 2025. 293 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

Proffitt & Goodson reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
Proffitt & Goodson sold 62 Genmab shares in Q4 2025, an estimated $1.9K.
Proffitt & Goodson first reported a position in Genmab in Q3 2025 and held it in 1 quarter.
Proffitt & Goodson's Genmab position peaked at $1.9K in Q3 2025.
293 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Proffitt & Goodson's 13F filing for Q4 2025, filed 27 Jan 2026.